Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 651 - 660 of 742 studies

Neurological

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (XPF-010-303)

Metabolic and Endocrine

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Cancer and neoplasms

A Phase Iii, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib In Combination With Phesgo Versus Placebo In Combination With Phesgo After First Line Induction Therapy In Participants With Pik3ca‑Mutated Her2-Positive Locally Advanced Or Metastatic Breast Cancer (INAVO122)

NIHR BioResource for Translational Research - linked to NIHR203975 PID 16514

Cancer and neoplasms

Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors (AZD5863)

Cancer and neoplasms

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GEMINI Gastric)

NIHR HIC Patient Blood Management and Perioperative Care

Transcranial ultrasound to disrupt pathological oscillations in the brain of people with Parkinson’s Disease and other neurological disorders

Cancer and neoplasms

A Phase 1/2 open-label multi-centre study to assess the safety, pharmacokinetics, and anti-tumour activity of GTAEXS617 in patients with advanced solid tumours

Cancer and neoplasms

A modular, multi-arm, first in human trial to evaluate the safety and tolerability of MDX-124 alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies (ATTAINMENT)